Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

OTLK - Outlook Therapeutics Inc Stock Price, Fair Value and News

$1.57+0.09 (+6.08%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

OTLK Price Action

Last 7 days

2.7%

Last 30 days

-8.9%

Trailing 12 Months

-78%

OTLK RSI Chart

JunJulAugSepOctNovDec2025FebMar0102030405060708090

OTLK Valuation

Market Cap

49.3M

Price/Earnings (Trailing)

-1.05

Price/Sales (Trailing)

7.34

EV/EBITDA

-0.55

Price/Free Cashflow

-0.74

OTLK Price/Sales (Trailing)

20222023202420250102030405060

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

OTLK Fundamentals

OTLK Revenue

Revenue (TTM)

8.1M

201520162017201820192M4M6M8M10M

OTLK Earnings

Earnings (TTM)

-46.8M

Earnings Growth (Yr)

255.46%

Earnings Growth (Qtr)

205.34%

20162018202020222024-150M-100M-50M0

OTLK Profitability

EBT Margin

-947.40%

Return on Equity

93.08%

Return on Assets

-275.26%

Free Cashflow Yield

-135.34%

OTLK Investor Care

Shares Dilution (1Y)

146.04%

Diluted EPS (TTM)

-4.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
201520162017201820191M2M3M4M5M6M7M8M9M10M
Net sales
YearQ1Q2Q3Q4
20193.3M3.1M8.1M0
20184.7M5.2M3.1M3.4M
20171.6M1.4M3.8M4.3M
20163.8M3.0M3.0M2.3M
20157.8M6.5M5.2M3.3M
2014009.1M0
Get all data in R, Python etc through our Historical Stock Data APIs

About Outlook Therapeutics Inc

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
 CEO
 WEBSITEoutlooktherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES17

Outlook Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Outlook Therapeutics Inc? What does OTLK stand for in stocks?

OTLK is the stock ticker symbol of Outlook Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Outlook Therapeutics Inc (OTLK)?

As of Wed Mar 12 2025, market cap of Outlook Therapeutics Inc is 49.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OTLK stock?

You can check OTLK's fair value in chart for subscribers.

Is Outlook Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether OTLK is over valued or under valued. Whether Outlook Therapeutics Inc is cheap or expensive depends on the assumptions which impact Outlook Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OTLK.

What is Outlook Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 12 2025, OTLK's PE ratio (Price to Earnings) is -1.05 and Price to Sales (PS) ratio is 7.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OTLK PE ratio will change depending on the future growth rate expectations of investors.